Autres langues Teva Pharmaceutical Industries Limited TEL AVIV STOCK EXCHANGE

Actions

TEVA

IL0006290147

Marché Fermé - TEL AVIV STOCK EXCHANGE Autres places de cotation 16:24:19 06/05/2024			Varia. 5j.	Varia. 1 janv.
5 207 ^ILa	+1,19%		+5,55%	+36,49%

30/04	La FTC conteste les listes de brevets "inutiles" pour Ozempic, Victoza et d'autres médicaments	MT
30/04	Les principaux événements de la mi-journée : Les actions d'Eli Lilly et de HSBC bénéficient d'un coup de pouce après la publication des résultats ; BBVA envisage une fusion avec Sabadell ; la FTC conteste 300 listes de brevets "inutiles".	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Teva's 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious Targets	03/05
Teva to Present at the 2024 Bank of America Healthcare Conference	03/05
Teva’s 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious Targets	02/05
Alvotech - U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-FreeInterchangeable Biosimilar to Humira	01/05
HINTERGRUND/FTC knöpft sich Patentanmeldungen für Arzneimittel vor	01/05
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	30/04
Top Midday Stories: Shares of Eli Lilly, HSBC Get Post-Earnings Bump; BBVA Exploring Merger With Sabadell; FTC Disputes 300 'Junk' Patent Listings	30/04
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	30/04
Alvotech to Manufacture Humira Biosimilar for Quallent Pharmaceuticals	30/04
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	30/04
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	30/04
Alvotech to Make Humira Biosimilar Adalimumab-ryvk for Quallent	30/04
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)	30/04
Vanda Pharmaceuticals Appeal for Patents on Sleep Drug Declined by US Supreme Court	22/04
Alvotech Shares Rise After Signing Agreement to Expand Access to Humira Biosimilar Adalimumab-ryvk in US	19/04
Alvotech Signs Agreement to Expand Access to Humira Biosimilar Adalimumab-ryvk in US	19/04
Teva's New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO Tablets	17/04
Alvotech and Teva Announces U.S. FDA Approval of SELARSDI (ustekinumab-aekn), biosimilar to Stelara (ustekinumab)	17/04
Alvotech, Teva Win US FDA Approval for Selarsdi Injection to Treat Severe Plaque Psoriasis, Psoriatic Arthritis	16/04
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)	16/04

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

A la une

Teva Pharmaceutical Industries Limited : Doit encore lâcher du lest

Le 01 février 2024 à 10:03

INTERVIEW - Richard Francis, PDG de Teva Pharmaceutical : trimestre solide, prévisions annuelles relevées

Le 02 août 2023 à 21:19